Program

Program Tuesday, 1 November 2016

7:30 - 8:30
EDUCATIONAL SYMPOSIUM
7:30 - 8:30
Room: Hall D (L -2)
NEW VALUE FRAMEWORKS IN THE UNITED STATES: INSIGHTS FROM PAYERS, CONSIDERATIONS FOR MANUFACTURERS, AND IMPLICATIONS FOR OTHER REGIONS OF THE WORLD

(Sponsored by Xcenda)

7:30 - 8:30
OPEN MEETING: ISPOR STATED PREFERENCE METHODS SPECIAL INTEREST GROUP
Room: Hall G1 (L -2)
Stated-preference methods are increasingly used to support health care decision making across Europe.  Multiple methods can be used to measure preferences of patients and other stakeholders.  The next project is a manuscript mapping the use of stated preference methods in the EU.  Examples include: IQWiG’s benefit assessments requiring elicitation of patient preferences using discrete choice experiment (DCE) or the analytical hierarchy process (AHP) and the use of direct weighting methods to elicit decision makers’ preferences to inform reimbursement decisions by HTA agencies in Hungary and Italy.  If you are interested in the topic and /or have case studies to contribute, please join the discussion! 
8:45 - 9:45
BREAKOUT SESSION

8:45 - 9:45
Room: Hall E1 (L0)

IP9: INCENTIVISING RESEARCH INTO THE EFFECTIVENESS OF MEDICAL DEVICES

Moderator:

Rosanna Tarricone, PhD, Professor, Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy

Panelists:

Michael F Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Mirella Marlow, MBA, MA, Programme Director, Devices and Diagnostics Systems, NICE (National Institute for Health and Clinical Excellence), London, UK

Adrian Griffin, MSc, Vice President HTA & Reimbursement Policy, Johnson & Johnson, High Wycombe, UK


8:45 - 9:45
Room: Hall A (L2)
W10: THE POTENTIAL AND PITFALLS OF USING MULTI-CRITERIA DECISION ANALYSIS TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT
Discussion Leaders:

Janine A. van Til, PhD, Assistant Professor Preference Research, Health Technology and Services Research, University of Twente, Enschede, The Netherlands

Rob Baltussen, PhD, Associate Professor Health Economics, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands

Michele Tringali, MD, Director, HTA Program, Lombardy Region Health Directorate, Milan, Italy

Susanne Schmitz, PhD, Postdoctoral Fellow, Department of Population Health / Health Economics and Evidence Synthesis Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg


8:45 - 9:45
Room: Hall D (L -2)
W11: LET'S GO FLY A KITE - MANAGING THE WINDS OF CHANGE IN REAL WORLD EVIDENCE STUDIES
Discussion Leaders:

Alison Bourke, BSc, MSc, Scientific Director Real-World Evidence Solutions, IMS Health, London, UK

Andrew Bate, PhD, Senior Director, Epidemiology Group Lead, Analytics & Worldwide Safety, Pfizer Ltd, Surrey, UK

Gillian C Hall, PhD, Consultant in Pharmacoepidemiology, Gillian Hall Epidemiology Ltd, London, UK


8:45 - 9:45
Room: Hall E2 (L0)
W12: RETHINKING WHAT MISSING PATIENT-REPORTED OUTCOME (PRO) DATA CAN TEACH US ABOUT OUTCOMES AND SURVIVAL IN ONCOLOGY CLINICAL TRIALS
Discussion Leaders:

Mark E. Boye, PhD, Principal Scientist, Eli Lilly and Company, Indianapolis, IN, USA

Katherine Houghton, MSc, Associate Director, Health Economics, RTI Health Solutions, Durham, NC, USA

Donald E Stull, PhD, Head, Data Analytics and Design Strategy, Health Economics, RTI Health Solutions, Durham, NC, USA


8:45 - 9:45
Room: Hall F1 (L0)
P7: NEUROLOGICAL DISORDERS STUDIES
Moderator: Paolo Angelo Cortesi, PhD
Researcher, Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy

ND1

8:45 - 9:00

BURDEN AND WORK PRODUCTIVITY LOSS IMPAIRMENT FROM PROVIDING CARE TO ALZHEIMER'S DISEASE PATIENTS

Hu X1, Ritchie C2, Wood R3, Jones E3, Black CM4, Khandker RK4, Ambegaonkar BM4
1University of Southern California, Los Angeles, CA, USA, 2University of Edinburgh, Edinburgh, UK, 3Adelphi Real World, Bollington, UK, 4Merck & Co., Inc., Rahway, NJ, USA

ND2

9:00 - 9:15

ADVANCED PARKINSON’S DISEASE IN STOCKHOLM COUNTY, SWEDEN – HOW MANY ARE THEY AND WHAT ARE THE REAL-LIFE HEALTH CARE COSTS?

Eriksson JK1, Anell B2
1Karolinska Institute, Stockholm, Sweden, 2Parexel International, Stockholm, Sweden

ND3

9:15 - 9:30

THE COST OF MULTIPLE SCLEROSIS IN 16 EUROPEAN COUNTRIES: FUNCTIONAL STATUS, SYMPTOMS AND MENTAL FACTORS DRIVE COSTS

Berg J1, Gannedahl M1, Capsa D1, Eriksson J2, Thompson A3, Kobelt G4
1Mapi, Stockholm, Sweden, 2Mapi Group, Stockholm, Sweden, 3University College London, London, UK, 4European Health Economics, Mulhouse, France

ND4

9:30 - 9:45

EXCESS COSTS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA IN THE ELDERLY

Menzin J, Park SS
Boston Health Economics, Waltham, MA, USA

8:45 - 9:45
Room: Hall F2 (L0)
P8: PATIENT PREFERENCE STUDIES
Moderator: Andrew J. Lloyd, DPhil
VP (Practice Lead), Patient Reported Outcomes, Oxford Outcomes, An ICON plc Company, Oxford, UK

PP1

8:45 - 9:00

NINE TESTS FOR ASSESING VALIDITY OF A DISCRETE-CHOICE EXPERIMENT

Janssen EM, Bridges JF
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PP2

9:00 - 9:15

HETEROGENEOUS PREFERENCES FOR DELAYING ONSET OF ALZHEIMER’S DISEASE AMONG OLDER ADULTS IN THE US

Reed SD1, Yang J1, Disantostefano R2, Streffer J3, Levitan B2, Johnson FR1
1Duke Clinical Research Institute, Durham, NC, USA, 2Janssen R&D, Titusville, NJ, USA, 3Janssen R&D, Beerse, Belgium

PP3

9:15 - 9:30

PATIENTS' PREFERENCES FOR CHARACTERISTICS OF PERIODONTAL DISEASE AND ITS' TREATMENT: A DISCRETE CHOICE EXPERIMENT

Vennedey V1, Danner M1, Civello D1, Schwalm A2, Seidl A2, Hiligsmann M3, Stock S1
1University Hospital Cologne, Cologne, Germany, 2Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 3Maastricht University, Maastricht, The Netherlands

PP4

9:30 - 9:45

COMPARING PREFERENCES OF PATIENTS WITH RHEUMATIC DISEASES, OF EXPERIENCED RHEUMATOLOGISTS, NURSES AND PHARMACISTS TOWARD THE TREATMENT OF RHEUMATIC DISEASES WITH BIOLOGICAL AGENTS: RESULTS FROM THE CARA STUDY

Scalone L1, Cortesi PA1, Sarzi-Puttini P2, Sinigaglia L3, Montecucco C4, Giacomelli R5, Lapadula G6, Olivieri I7, Giardino AM8, Mecchia M8, Mantovani LG1
1University of Milano-Bicocca, Monza, Italy, 2Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, 3Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, 4University of Pavia, Pavia, Italy, 5University of L'Aquila, L'Aquila, Italy, 6University of Bari, Bari, Italy, 7Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera, Italy, 8MSD Italy, Rome, Italy
8:45 - 13:45
RESEARCH POSTER PRESENTATIONS - SESSION III
9:45 - 10:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III
10:15 - 12:00
WELCOME & SECOND PLENARY SESSION
Room: Hall A (L2)
WELCOME FROM ISPOR PRESIDENT
Lou Garrison, PhD bio
2016-2017 ISPOR President and Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
Room: Hall A (L2)
WELCOME FROM ISPOR CHIEF SCIENCE OFFICER
Richard J. Willke, PhD
Chief Science Officer, ISPOR, Lawrenceville, NJ, USA
Room: Hall A (L2)
2016 ISPOR MARILYN DIX SMITH LEADERSHIP AWARD
Presented by: Scott D. Ramsey, MD, PhD, Chair, ISPOR Marilyn Dix Smith Leadership Award Committee
J. Jaime Caro, MDCM, FRCPC, FACP
Chief Scientist, Evidera, Lexington, MA, USA and, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada
Room: Hall A (L2)
SECOND PLENARY SESSION: DIFFERENTIAL PRICING OF MEDICINES IN EUROPE: IMPLICATIONS FOR ACCESS, INNOVATION, AND AFFORDABILITY
Each year only 30 to 40 new patent-protected medicines are launched worldwide.  From an economic perspective, they are unique global public goods—with high average fixed costs of development and low marginal costs of production and distribution.  Given differences among countries in their ability and willingness to pay for healthcare, health economists have long argued that differential pricing for medicines across countries could improve global dynamic efficiency.  But law in the European Union supporting the free movement of goods makes it difficult to maintain different prices in different countries.  Countries have resorted to referencing prices in other countries to support their local pricing policies and negotiations, and have developed schemes that allow them to obtain confidential discounts.  The resulting patterns of price differences and access limitations are falling far short of what a coherent approach might produce.  This session will explore options for a defined and systematic approach to promoting efficient differential pricing in Europe.  Operational and political feasibility are key considerations in moving toward a sustainable policy.
Moderator: Lou Garrison, PhD bio
Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
Speaker: Sabine Vogler, PhD
Program Coordinator, Pharmacoeconomics and Pharmaceutical Policy Analysis, Head of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute), Vienna, Austria
Speaker: Jo De Cock
Chief Executive Officer, National Institute of Health and Disability Insurance (NIHDI), Brussels, Belgium
Speaker: Panos Kanavos, PhD
Associate Professor & Deputy Director, LSE Health, Department of Social Policy, London School of Economics, London, UK
Speaker: Adrian Towse, MA, MPhil bio
Director, Office of Health Economics, London, UK
12:00 - 13:45
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III
12:15 - 13:30
OPEN MEETING: PATIENT ENGAGEMENT, PATIENT CENTRIC, WHAT DOES IT ALL MEAN?
Room: Hall E1 (L0)
Join the ISPOR Patient Centered Special Interest Group for a discussion on their findings from a systematic review conducted on patient engagement and related terms and definitions, especially in the context of research, drug development, and health care decision making. Attendees interested in this topic are encouraged to provide input and feedback on the common definitions and identify key attributes that should be included in definitions.  
12:30 - 13:30
EDUCATIONAL SYMPOSIUM
12:30 - 13:30
Room: Hall D (L -2)
NOVEL APPROACHES TO EVIDENCE-DRIVEN DESIGN AND STUDY SAMPLE-FRAME VALIDATION

(Sponsored by QuintilesIMS)

12:45 - 13:45
POSTER AUTHOR DISCUSSION HOUR - SESSION III
13:45 - 14:45
BREAKOUT SESSION

13:45 - 14:45
Room: Hall A (L2)

IP10: ADAPTIVE PATHWAYS AND PATIENT ACCESS – PUSHING PAYER BOUNDARIES OR FACILITATING NEW PAYMENT MODELS?

Moderator:

Jacoline Bouvy, PhD, Scientific Adviser, National Institute for Health and Care Excellence (NICE), London, UK

Panelists:

Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicine Agency, London, UK

Ad Schuurman, MSc, MBA, President of MEDEV, Zorginstituut Nederland, Diemen, The Netherlands

Claudine Sapede, PharmD, MSc, Global HTA & Payment Policy Lead, F. Hoffmann-La Roche Ltd, Basel, Switzerland


13:45 - 14:45
Room: Hall D (L -2)

IP11: EMERGING US VALUE FRAMEWORKS: ARE THERE LESSONS FROM - OR FOR - EUROPE? (Invited Issue Panel)

Moderator:

Richard J. Willke, PhD, Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA bio

Panelists:

Peter J. Neumann, ScD, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts University, Boston, MA, USA bio

Michael F Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Finn Børlum Kristensen, MD, PhD, Professor, University of Southern Denmark, Hilleroed, Denmark bio


13:45 - 14:45
Room: Hall E1 (L0)
W13: CHANGING OUR PERSPECTIVE ON PATIENT-REPORTED OUTCOMES IN ONCOLOGY: IT’S MORE COMPLEX THAN TRADITIONALLY CONCEPTUALIZED OR ANALYZED
Discussion Leaders:

Mark E. Boye, PhD, Principal Scientist, Eli Lilly and Company, Indianapolis, IN, USA

Donald E Stull, PhD, Head, Data Analytics and Design Strategy, Health Economics, RTI Health Solutions, Durham, NC, USA

Claire Ainsworth, BSc, Research Analyst, Health Economics, RTI Health Solutions, MANCHESTER, UK


13:45 - 14:45
Room: Hall E2 (L0)
W14: CHOICE DEFINES VALUE: HOW TO ANALYSE AND DISSEMINATE EVIDENCE ON THE IMPORTANCE OF MULTIPLE CRITERIA FROM MULTIPLE PERSPECTIVES TO INFORM AN APPRAISAL PROCESS IN HEALTH TECHNOLOGY ASSESSMENT
Discussion Leaders:

Benjamin M. Craig, PhD, Associate Professor, Department of Economics, University of South Florida and Assistant Member, Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA

Axel Mühlbacher, PhD, Professor, Health Economics and Health Care Management, IGM, Hochschule Neubrandenburg, Neubrandenburg, Germany

Juan Marcos Gonzalez, PhD, Senior Research Economist, RTI Health Solutions, Research Triangle Park, NC, USA

Juan Manuel Ramos-Goñi, MSc, PhD, Senior Researcher, EuroQol Research Foundation, Rotterdam, The Netherlands


13:45 - 14:45
Room: Hall F2 (L0)
P9: ECONOMIC EVALUATION STUDIES
Moderator: Adam Hutchings, MSc
Director, Dolon Ltd, London, UK

EE1

13:45 - 14:00

ECONOMIC EVALUATION FOR THE UNITED KINGDOM OF SYSTEMIC CHEMOTHERAPIES AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC CANCER

Gharaibeh M1, McBride A2, Alberts D2, Slack M1, Erstad B1, Abraham I1
1University of Arizona, Tucson, AZ, USA, 2Arizona Cancer Center, Tucson, AZ, USA

EE2

14:00 - 14:15

IS IT REALLY COST-EFFECTIVE TO RISK-ASSESS ALL HOSPITALIZED PATIENTS FOR PRESSURE ULCERS EVERY NURSING-SHIFT?

Padula WV1, Onyekwere U1, Makic MB2, Wald HL2, Epstein Z3, Meltzer DO4
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2University of Colorado, Aurora, CO, USA, 3Pomona College, Claremont, CA, USA, 4University of Chicago, Chicago, IL, USA

EE3

14:15 - 14:30

THE COST-EFFECTIVENESS OF BARIATRIC SURGERY IN GERMANY, FRANCE, ITALY AND THE UNITED KINGDOM

Belarbi S1, Kusel J2, Thomas MG2
1Ethicon SAS, Issy-Les-Moulineaux, France, 2Costello Medical Consulting Ltd, Cambridge, UK

EE4

14:30 - 14:45

COST EFFECTIVENESS OF NIVOLUMAB MONOTHERAPY FOR THE TREATMENT OF ADVANCED MELANOMA PATIENTS IN THE UNITED KINGDOM

Meng Y1, Hertel N2, Ellis J2, Johnson H3, Philips Z1, Roskell N1, Lee D1
1BresMed Health Solutions, Sheffield, UK, 2Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK, 3Helen Johnson Consulting Ltd, Welwyn Garden City, UK

13:45 - 14:45
Room: Hall F1 (L0)
P10: HTA & VALUE ASSESSMENT STUDIES
Moderator: Petra Schnell-Inderst, MPH, Dipl. Biol
Senior Scientist, Head, Program on Health Technology Assessment Institute of Public Health, Medical Decision Making and Health Technology Assessment Dept. of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

HT5

13:45 - 14:00

DEVELOPMENT OF A MULTI-CRITERIA DECISION ANALYSIS (MCDA) FRAMEWORK FOR HEALTH CARE DECISION-MAKING IN CATALONIA (SPAIN): PILOT STUDY FOCUSED IN ORPHAN DRUGS

Gilabert-Perramon A1, Torrent-Farnell J2, Catalan A3, Prat A4, Fontanet M2, Puig-Peiró R5, Merino-Montero S6, Khoury H7, Goetghebeur MM8, Badia X6
1Catalan Health Service, Government of Catalonia, Barcelona, Spain, 2Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 3Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Barcelona, Spain, 4Servei Català de la Salut (CatSalut), Barcelona, Spain, 5Catalan Health Service (CatSalut), Barcelona, Spain, 6Omakase Consulting, Barcelona, Spain, 7LASER Analytica, Montreal, QC, Canada, 8LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada

HT6

14:00 - 14:15

CRITERIA DRIVING VALUES ASSESSMENTS IN MULTIPLE SCLEROSIS MEDICINES

Visintin E1, Kanavos P2
1London School of Economics and Political Sciences, London, UK, 2London School of Economics and Political Science, London, UK

HT7

14:15 - 14:30

HTA AGENCIES PERSPECTIVE ON PROGRESSION-FREE-SURVIVAL (PFS)

Schmitter S1, Holzerny P2, Brock E2, Günzel C3, Ruckdäschel S2
1Pfizer Deutschland GmbH, Berlin, Germany, 2HealthEcon AG, Basel, Switzerland, 3Pfizer Pharma GmbH, Berlin, Germany

HT8

14:30 - 14:45

DEFINING THE VALUE: DO THE NEW ONCOLOGY FRAMEWORKS IN THE US AIM AT OBJECTIVE VALUATION? – A CASE STUDY IN MULTIPLE MYELOMA

Forsythe A1, Pezalla EJ2
1PS HTA, New York, NY, USA, 2Enlightenment BioConsult, LLC., Wethersfield, CT, USA
14:45 - 15:15
BREAK & EXHIBITS VIEWING
15:15 - 16:15
BREAKOUT SESSION

15:15 - 16:15
Room: Hall F1 (L0)

IP12: VALUING TRANSFORMATIVE MEDICINES IN RARE DISEASES: METHODS AND MADNESS

Moderator:

Paul Hodgkins, PhD, Vice President, Vertex Pharmaceuticals Incorporated, Boston, MA, USA

Panelists:

Ron Akehurst, DSc, Strategic Director, BresMed Health Solutions, Sheffield, UK

Alastair Kent, OBE, Director, Genetic Alliance UK, London, UK

Maarten Postma, PhD, Professor Pharmacoeconomics, Pharmacy Dept, University of Groningen, Groningen, The Netherlands


15:15 - 16:15
Room: Hall E1 (L0)
W15: BUILDING AND APPLYING CONSTRAINED OPTIMIZATION MODELS IN HEALTH CARE: A CASE STUDY OF OPTIMAL KIDNEY MATCHING
Discussion Leaders:

William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

Alec Morton, PhD, Professor, Management Science, University of Strathclyde, Glasgow, UK

William V. Padula, PhD, Assistant Professor, Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Praveen Thokala, MASc, PhD, Research Fellow, Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK


15:15 - 16:15
Room: Hall A (L2)
W16: HOW TO TRANSFER ECONOMIC EVIDENCE TO LOW AND MIDDLE-INCOME COUNTRIES? WORKING UNDER CAPACITY RESTRICTIONS
Discussion Leaders:

Zoltan Kalo, MD, PhD, Professor of Health Economics & Head of the Institute of Economics, Eötvös Loránd University, Budapest, Hungary

Johan L. Severens, PhD, Professor of Evaluation in Health Care, Institute of Health Policy & Management, Institute of Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands

Olena Mandrik, PhD, Postdoc Researcher, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

Saskia Knies, PhD, Advisor Pharmacoeconomics, National Health Care Institute, Diemen, The Netherlands


15:15 - 16:15
Room: Hall E2 (L0)
W17: NEW CHALLENGES FOR HIGH-RISK MEDICAL DEVICES IN EUROPE: HOW TO ACHIEVE THE BALANCE BETWEEN THE DEMAND FOR EARLY PRODUCT LAUNCH AND SAFETY?
Discussion Leaders:

Bernard Avouac, MD, Former president of Transparency Commission, Medecin des Hopitaux de Paris, Paris, France

Jenifer Ehreth, PhD, MHA, Executive & Scientific Vice President, LASER Analytica, Paris, France

Rosanna Tarricone, PhD, Professor, Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy

Katerina Zakrzewska, PhD, Senior Director, Strategic and Medical Affairs, EMEA, Diabetes Care Companies, Johnson & Johnson, Zug, Switzerland


15:15 - 16:15
Room: Hall D (L -2)
P11: DATABASE USE IN OUTCOMES RESEARCH STUDIES
Moderator: Joseph E. Biskupiak, PhD, MBA
Research Professor, Pharmacotherapy, University of Utah, Salt Lake City, UT, USA

DB1

15:15 - 15:30

MORTALITY EXCESS DUE TO CLOSTRIDIUM DIFFICILE INFECTION - A NATIONAL DATABASE ANALYSIS

Bouee S1, Levy Bachelot L2, Ravonimbola H2, Longepierre L1, Godard C2, Gourmelen J3, Barbut F4
1CEMKA, Bourg La Reine, France, 2MSD France, Courbevoie, France, 3UMS 011 - Inserm - UVSQ, Villejuif, France, 4Laboratory for Clostridium Difficile, Paris, France

DB2

15:30 - 15:45

A RETROSPECTIVE STUDY ON ASSOCIATION BETWEEN CHANGE IN BMI AND INCIDENCE OF HYPERTENSION USING A HEALTH CARE DATABASE IN JAPAN

Yamamoto Y1, Tanabe K2, Takahashi S2, Ii Y2, Kitazaki S1, Fujimoto Y2
1MinaCare Co. Ltd, Tokyo, Japan, 2Pfizer Japan Inc, Tokyo, Japan

DB3

15:45 - 16:00

ACCURACY OF NATURAL LANGUAGE PROCESSING-BASED CLASSIFIERS FOR AUTOMATED IDENTIFICATION OF ABSTRACTS OF STUDIES ON HUMANISTIC AND ECONOMIC BURDEN OF DISEASE

Krohn J1, Martin A2, Martin C2
1Krohn Consulting Ltd, Coventry, UK, 2Crystallise Ltd., London, UK

DB4

16:00 - 16:15

USE OF DATA-MINING TO PERFORM A REAL WORLD COST ANALYSIS OF HER2-POSITIVE BREAST CANCER IN IRAN

Ansaripour A1, Zendehdel K2, Tadayon N3, Sadeghi F4, Uyl-de Groot C5, Redekop WK6
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Tehran Medical Sciences and Medical Education University, Tehran, Iran, 3Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of), 4Tehran Medical Sciences and Medical education University, Tehran, Iran, 5National Health Care Institute, Diemen, The Netherlands, 6National University of Singapore, Singapore, Singapore

15:15 - 16:15
Room: Hall F2 (L0)
P12: HEALTH CARE EXPENDITURE & REIMBURSEMENT STUDIES
Moderator: Jeanette Kusel, MSci, MSc
Head of HTA and Health Economics, Costello Medical Consulting Ltd, Cambridge, UK

HC1

15:15 - 15:30

MODELING THE IMPACT OF REFORM TO THE CANCER DRUGS FUND

Karlsberg Schaffer S, Garau M, O'Neill P, Bianchi S
Office of Health Economics, London, UK

HC2

15:30 - 15:45

ECONOMIC BURDEN OF DISEASES IN FRANCE: ANALYSING THE TRENDS FROM 2012 TO 2014, USING THE FRENCH HEALTH INSURANCE DATABASE (SNIIRAM)

Gastaldi Menager C1, Drouin J2, Pestel L3, Fagot-Campagna A2, Gissot C3
1CNAMTS, Paris, France, 2CNAMTS (National Health Insurance), Paris Cedex 20, France, 3CNAMTS (National Health Insurance), Paris, France

HC3

15:45 - 16:00

THE RELATIONSHIP BETWEEN MEDICAL INNOVATION AND HEALTH EXPENDITURES

Cinaroglu S1, Guzel E2, Baser O3
1Hacettepe University, Ankara, Turkey, 2Eastern Michigan University, Ypsilanti, MI, USA, 3Columbia University/MEF University/STATinMED Research, New York, NY, USA

HC4

16:00 - 16:15

COMPARISON OF TIME TO REIMBURSEMENT DECISION OF INNOVATIVE PHARMACEUTICALS IN EUROPE

Hernandez J, Nientker K, Hensen M
Pharmerit International, Rotterdam, The Netherlands
15:15 - 19:15
RESEARCH POSTER PRESENTATIONS - SESSION IV
16:30 - 17:30
BREAKOUT SESSION

16:30 - 17:30
Room: Hall A (L2)

IP13: REAL WORLD EVIDENCE TO SUPPORT VALUE PROPOSITION AND REIMBURSEMENT AT LAUNCH: THE ASPIRATIONAL MEETS THE IMPRACTICAL?

Moderator:

Kari Edwards, PhD, Managing Partner, Harbinger Health, LLC, Los Angeles, CA, USA

Panelists:

Adrian R. Levy, PhD, Professor & Head, Community Health and Epidemiology, Dalhousie University, Nova Scotia, AL, Canada

Arie Barlev, PharmD, MS, Senior Director, Health Economics and Outcomes Research, Medivation, Inc., San Francisco, CA, USA

Andrew Briggs, DPhil, William R Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK


16:30 - 17:30
Room: Hall E2 (L0)
W18: METHODOLOGIES FOR EVALUATING GEOGRAPHIC VARIATION IN HEALTH CARE OUTCOMES RESEARCH
Discussion Leaders:

Rajesh Balkrishnan, PhD, Professor, Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA

Gregoire Mercier, MD, PhD, Head, Economic Evaluation Unit, CHU Montpellier, Montpellier, France

Vera Georgescu, PhD, Head, Economic Evaluation Unit, CHU Montpellier, Montpellier, France


16:30 - 17:30
Room: Hall E1 (L0)
W19: STRENGTHENING THE ROLE OF VALUE OF INFORMATION ANALYSIS IN HEALTH TECHNOLOGY ASSESSMENT: KNOWN CHALLENGES AND PROPOSED SOLUTIONS
Discussion Leaders:

Elisabeth Fenwick, PhD, Principal of Health Economics, ICON Health Economics & Epidemiology, Abingdon, UK

Claire Rothery, PhD, Senior Research Fellow in Health Economics, Centre for Health Economics, University of York, York, UK

Hendrik Koffijberg, PhD, Associate Professor, Department of Health Technology & Services Research, MIRA institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands

David Glynn, MSc, PhD student, Centre for Health Economics, University of York, York, UK


16:30 - 17:30
Room: Hall D (L -2)
W20: PREDICTING TREATMENT EFFECTIVENESS OVER TIME IN REAL WORLD FROM TRIAL EFFICACY DATA
Discussion Leaders:

Keith Abrams, PhD, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK

Mark Belger, BSc, Principal Research Scientist, GSS, Eli Lilly, Ascot, UK

Sarah Garner, PhD, Associate Director for Science Policy and Research, National Institute for Health and Care Excellence, London, UK

Eva-Maria Didden, PhD, Researcher, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland


16:30 - 17:30
Room: Hall F1 (L0)
W21: DOUBLY ROBUST ESTIMATION FOR COMPARATIVE EFFECTIVENESS RESEARCH: GETTING AN EXTRA SHOT AT CORRECTLY SPECIFYING THE TREATMENT-OUTCOME MODEL
Discussion Leaders:

Patrick Lefebvre, MA, Managing Principal, Groupe d'analyse, Ltée, Montreal, QC, Canada

Maral DerSarkissian, PhD, Associate, Analysis Group, Inc., Los Angeles, CA, USA

Melvin "Skip" Olson, PhD, Head, RWD Strategy and Innovation, Novartis Pharma AG, Basel, Switzerland

Valéry Risson, PhD, MBA, Director, HEOR Excellence, Novartis Pharma AG, Basel, Switzerland


16:30 - 17:30
Room: Hall F2 (L0)
P13: MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES
Moderator: Rok Hren, PhD, MSc IHP(HE)
Assistant Professor, University of Ljubljana, Ljubljana, Slovenia

MD1

16:30 - 16:45

MEDICAL DEVICES: TIMELY ACCESS AND REIMBURSEMENT - CAN NATIONAL HEALTH TECHNOLOGY ASSESSMENT BODIES BE PART OF THE SOLUTION?

Macaulay R, Shaw S
Parexel Access Consulting, London, UK

MD2

16:45 - 17:00

TOWARDS IMPROVED CERVICAL CANCER PRIMARY SCREENING IN AUSTRIA - A DECISION-ANALYTIC BENEFIT-HARM ANALYSIS

Sroczynski G1, Esteban E1, Widschwendter A2, Oberaigner W3, Borena W2, von Laer D2, Hackl M4, Endel G5, Siebert U6
1UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, 2Medical University Innsbruck, Innsbruck, Austria, 3Tirol Kliniken Innsbruck, Innsbruck, Austria, 4Statistics Austria, Austrian National Cancer Registry, Directorate Social Statistics, Statistics Austria, Vienna, Austria, 5Main Association of Austrian Social Insurance Institutions, Vienna, Austria, 6and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

MD3

17:00 - 17:15

ADOPTION OF TRANSCATHETER MITRAL VALVE REPAIR IN GERMANY: UTILIZATION PATTERNS AND CASE VOLUMES COMPARED TO MITRAL VALVE SURGERY IN THE PERIOD 2010-2014

Pietzsch JB1, Weber SA2, Pietzsch ML2, Conradi L3
1Wing Tech Inc., Irvine, CA, USA, 2Cellogic GmbH, Berlin, Germany, 3University Heart Center Hamburg, Hamburg, Germany

MD4

17:15 - 17:30

DECISION UNCERTAINTY AND THE NEED FOR FURTHER RESEARCH: A CASE STUDY IN FENESTRATED ENDOVASCULAR ANEURYSM REPAIR FOR COMPLEX ABDOMINAL AORTIC ANEURYSMS

Ciani O1, Epstein D2, Rothery C3, Taylor RS1, Sculpher M3
1University of Exeter Medical School, Exeter, UK, 2University of Granada, Granada, Spain, 3University of York, Heslington, York, UK
17:30 - 19:15
EXHIBITORS' WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV
17:45 - 18:45
BREAKOUT SESSION

17:45 - 18:45
Room: Hall E1 (L0)
F8: NEW ISSUES & EMERGING TRENDS IN HEOR: REVISING THE ISPOR CODE OF ETHICS
Moderator:

Richard J. Willke, PhD, Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA bio

Speakers:

Jessica Santos, PhD, Global Compliance and Quality Director, Kantar Health, Epsom, UK

Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Louise Parmenter, PhD, Vice President, Epidemiology & Outcomes Research, Real-World & Late Phase Research, Quintiles, Inc., Reading, UK

Gurmit Sandhu, B Pharm (Hons), MBA, MPH, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland


17:45 - 18:45
Room: Hall F1 (L0)
F9: USES, APPLICATIONS, AND FUTURE DIRECTIONS OF THE ISPOR DIGEST OF INTERNATIONAL DATABASES
Moderator:

Carl Asche, PhD, MSc, Director, University of Illinois College of Medicine, Center for Outcomes Research, Peoria, IL, USA

Speakers:

Elisabeth M. Oehrlein, BA, PhD Candidate, Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA

Brian Seal, RPh, MBA, PhD, Director, Global Outcomes Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA


17:45 - 18:45
Room: Hall A (L2)
F10: HEALTH ECONOMIC MODELING IN ONCOLOGY
Moderator:

Noemi Muszbek, MSc, Senior Research Scientist, Evidera, London, UK

Speakers:

Sorrel Wolowacz, PhD, Senior Director, Market Access and Outcomes Strategy, RTI Health Solutions, Manchester, UK

Agnes Benedict, MSc, Executive Director, Evidera, Budapest, Hungary


17:45 - 18:45
Room: Hall E2 (L0)
F11: RESULTS FROM MCDA PAYER CRITERIA: WEIGHTS & PREFERENCES IN THE CEE REGION
Moderator:

Vladimir Zah, PhD Candidate and Chair, ISPOR CEE Network Executive Committee, Health Economist, Belgrade, Serbia

Speakers:

Oresta Piniazhko, PhD, PhD Candidate & Assistant Professor, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Tomas Dolezal, MD, PhD, Scientific Director, Institute of Health Economics and Technology Assessment, iHETA, Prague, Czech Republic

Ioannis Yfantopoulos, PhD, President, ISPOR Greece Chapter, and Professor of Health Economics, Economics and Political Science, University of Athens, Athens, Greece

Aleksandra Zawodnik, MSc Pharm, PhD Candidate, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland


17:45 - 18:45
Room: Hall D (L -2)
F12: THE VALUE OF MULTI-STAKEHOLDER PARTNERSHIP IN ADVANCING PATIENT ACCESS IN CENTRAL AND EASTERN EUROPE
Moderator:

Dominik Tomek, PharmD, MPH, PhD, President, ISPOR Slovakia Chapter, and Senior Researcher, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic

Speakers:

Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium

Stanimir Hasurdjiev, MD, Secretary-General, Patient Access Partnership, Brussels, Belgium

Tamas Agh, MD, PhD, Principal Researcher, Syreon Research Institute, Budapest, Hungary

Martin Višňanský, PharmDr., MBA, PhD, MSc, Lecturer, University of Veterinary Medicine and Pharmacy, Kosice, Slovakia


17:45 - 18:45
Room: Hall F2 (L0)
F13: THE SPANISH EXPERIENCE IN HEPATITIS C: FRIENDS OR FOES?
Moderator:

Carme Pinyol, MD, PhD, MSc, Director INNOVA STRATEGIC CONSULTING, President ISPOR Regional Spain Chapter, Barcelona, Spain

Speakers:

Pedro Gómez-Pajuelo, Health Economist, Ministry of Health, Madrid, Spain

Álvaro Hidalgo, PhD, Professor, Universidad de Castilla la Mancha, Toledo, Spain

Toni Gilabert, PhD, General Director of Medicines, Catalan Health Services, Barcelona, Spain

Iñaki Betolaza, Director of Pharmacy, Health Department of Basque Government, Vitoria-Gasteiz, Spain

18:15 - 19:15
POSTER AUTHOR DISCUSSION HOUR - SESSION IV
20:00 - 23:30
ISPOR SOCIAL EVENT

Join us at the historic Grand Festival Hall of Vienna’s City Hall for dinner, dancing and fun! This Gothic building is one of the most splendid in the city, with a tower reaching almost 98 meters high. Lighted by magnificent chandeliers, you will take a trip back in time with your ISPOR colleagues. Separate registration is required.

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.